MARSHALL WACE ASIA Ltd Takes Position in HCA Healthcare Inc (NYSE:HCA)
MARSHALL WACE ASIA Ltd acquired a new stake in HCA Healthcare Inc (NYSE:HCA) during the 1st quarter, HoldingsChannel reports. The institutional investor acquired 15,969 shares of the company’s stock, valued at approximately $2,082,000.
Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc grew its position in shares of HCA Healthcare by 0.3% during the 3rd quarter. Vanguard Group Inc now owns 19,916,360 shares of the company’s stock worth $2,770,765,000 after buying an additional 66,808 shares in the last quarter. Magellan Asset Management Ltd grew its position in shares of HCA Healthcare by 2.0% during the 1st quarter. Magellan Asset Management Ltd now owns 12,908,938 shares of the company’s stock worth $1,683,067,000 after buying an additional 258,477 shares in the last quarter. Oregon Public Employees Retirement Fund grew its position in shares of HCA Healthcare by 16,494.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 11,119,359 shares of the company’s stock worth $89,000 after buying an additional 11,052,352 shares in the last quarter. Northern Trust Corp grew its position in shares of HCA Healthcare by 9.4% during the 4th quarter. Northern Trust Corp now owns 3,579,428 shares of the company’s stock worth $445,459,000 after buying an additional 307,157 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of HCA Healthcare by 10.0% during the 4th quarter. Geode Capital Management LLC now owns 3,414,676 shares of the company’s stock worth $424,189,000 after buying an additional 310,086 shares in the last quarter. 70.29% of the stock is currently owned by institutional investors.
HCA stock traded down $0.75 during trading on Friday, reaching $126.63. 748,765 shares of the company traded hands, compared to its average volume of 1,535,745. HCA Healthcare Inc has a 12 month low of $101.30 and a 12 month high of $147.42. The company has a market cap of $43.60 billion, a P/E ratio of 12.96, a PEG ratio of 1.02 and a beta of 0.76.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 3rd will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 1.26%. The ex-dividend date of this dividend is Friday, May 31st. HCA Healthcare’s dividend payout ratio (DPR) is presently 16.38%.
In other HCA Healthcare news, insider Jon M. Foster sold 44,281 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $122.28, for a total value of $5,414,680.68. Following the completion of the sale, the insider now directly owns 96,052 shares in the company, valued at $11,745,238.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 2.70% of the company’s stock.
A number of equities analysts have recently issued reports on the company. ValuEngine downgraded HCA Healthcare from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th. Deutsche Bank increased their price target on HCA Healthcare from $160.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Zacks Investment Research raised HCA Healthcare from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a research report on Friday, May 3rd. UBS Group increased their price target on HCA Healthcare from $164.00 to $172.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, Raymond James raised HCA Healthcare from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $115.00 to $135.00 in a research report on Tuesday, April 23rd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company. HCA Healthcare currently has a consensus rating of “Buy” and a consensus price target of $149.00.
TRADEMARK VIOLATION NOTICE: “MARSHALL WACE ASIA Ltd Takes Position in HCA Healthcare Inc (NYSE:HCA)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/marshall-wace-asia-ltd-takes-position-in-hca-healthcare-inc-nysehca/3042658.html.
HCA Healthcare Profile
HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.
See Also: What is Depreciation?
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare Inc (NYSE:HCA).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.